Market for chemicals to double in 20 years – US limits Avastin approval – And Arkema buys Chinese firms (more…)
November 2011
Monthly Archive
Chemistry World's round-up of money and molecules
Posted by Andrew on Wed 23 Nov 2011Categories: The Commercial Chemist | No Comments
This week on Chemistry World
Posted by Chemistry World on Mon 21 Nov 2011Categories: News , This week's stories | No Comments
20 November 2011: Have something to say about an article you’ve read on Chemistry World this week? Leave your comments below…
Chemistry World’s round-up of money and molecules
Posted by Andrew on Fri 18 Nov 2011Categories: The Commercial Chemist | No Comments
New boss at the EMA – US approval for Jakafi – And Novartis group claims new class against malaria (more…)
Chemistry in its element – strychnine
Posted by PhilR on Wed 16 Nov 2011Categories: Podcasts | No Comments
Many a crime writer has reached for the star of this week’s Chemistry in its element podcast. Simon Cotton scrutinises strychnine.
Chemistry World's round-up of money and molecules
Posted by Andrew on Wed 16 Nov 2011Categories: The Commercial Chemist | No Comments
This week on Chemistry World
Posted by Patrick on Mon 14 Nov 2011Categories: News , This week's stories | No Comments
13 November 2011: Have something to say about an article you’ve read on Chemistry World this week? Leave your comments below…
Chemistry World’s round-up of money and molecules
Posted by Phillip on Fri 11 Nov 2011Categories: The Commercial Chemist | No Comments
Mass resignation at Turkish science academy
Posted by Patrick on Thu 10 Nov 2011Categories: News | No Comments
In September Chemistry World reported that the Turkish science academy was fighting government interference in the appointment of its membership. Since then the Turkish government has pressed ahead with its plan to expand the number of academy members at TÜBA and appoint them itself, albeit through a committee that the government would hand pick.
As a result, 58 of the 138 academy members have resigned. Namik Aras, a US-trained nuclear chemist who is an honorary member of TÜBA, says that the members who resigned are now working to set up another academy free from government interference. They will meet again in a couple of weeks to assess the situation and decide how to proceed and how to fund the new academy.
Patrick Walter
US generics company Mylan is to create a ‘centre of excellence’ at the Pfizer R&D site in Sandwich, UK. Pfizer said in February that it would close the site within two years, putting 2400 jobs at risk.
Now, Mylan has struck a $17.5 million (£11 million) deal for the generic version of Advair Diskus (fluticasone, salmeterol) that Pfizer has been developing. Advair Diskus is a treatment against asthma and chronic obstructive pulmonary disorder (COPD) from UK pharma giant GlaxoSmithKline (GSK) delivered through a distinctive disk shaped dry powder inhalation unit. In connection with the deal, Mylan will employ ‘select key members’ to work at the respiratory development division to be established in Sandwich or to work in Cambridge, UK.
‘I would like to personally welcome to Mylan the talented former Pfizer employees who will be joining us,’ said Mylan chief executive Robert Coury.
Andrew Turley
Chemistry in its element – acetone
Posted by PhilR on Thu 10 Nov 2011Categories: Podcasts | No Comments
Warfare and beauty queens collide in this week’s Chemistry in its element podcast on acetone, with Lars Öhrström.
